Amanta Healthcare IPO
UpcomingAlready have an account? Apply now
Schedule of Amanta Healthcare
| Issue open date | 01 Sep 2025 |
| Issue close date | 03 Sep 2025 |
| UPI mandate deadline | 03 Sep 2025 (5 PM) |
| Allotment finalization | 04 Sep 2025 |
| Refund initiation | 08 Sep 2025 |
| Share credit | 08 Sep 2025 |
| Listing date | 09 Sep 2025 |
| Mandate end date | 18 Sep 2025 |
| Lock-in end date for anchor investors (50%) | 04 Oct 2025 |
| Lock-in end date for anchor investors (remaining) | 03 Dec 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Amanta Healthcare
Amanta Healthcare is a pharmaceutical formulations manufacturer incorporated in 1994. The company specializes in sterile liquid formulations and operates across multiple therapeutic segments including fluid therapy, respiratory care, ophthalmic, diluents, and irrigation solutions. Its manufacturing facility, located in Hariyala, Kheda district, Gujarat, is spread across over 66,000 square meters and is equipped with multiple LVP and SVP lines using ABFS and ISBM technologies. The company is WHO-GMP compliant and holds ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and ISO 45001:2018 certifications.
Financials of Amanta Healthcare
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹126 crores |
| Fresh Issue | ₹126 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Capital expenditure for setting up new manufacturing line of SteriPort | 70 (55.5%) |
| Capital expenditure for setting up new manufacturing line for SVP | 30.13 (24%) |
| General corporate purposes | 25.87 (20.5%) |
Strengths
- Established in 1994 with diversified pharmaceutical product portfolio
- Advanced sterile liquid manufacturing across wide volume range
- Certified facility with ISO, WHO-GMP, and advanced technologies
- Extensive domestic and global distribution and sales network
- Experienced leadership with skilled, qualified employee base
Risk factors
- High customer concentration poses revenue stability and dependency risks
- Delay in SteriPort/SVP expansion may impact growth plans
- Promoter guarantees tied to loans may affect operations
- Sterile liquid products carry serious product liability exposure
- Unsecured borrowings and personal guarantees increase financial vulnerability
Allotment Status for Amanta Healthcare
To check your allotment status – click here.